Dearborn Partners’s Pfizer PFE Stock Holding History

Dearborn Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$978K	Sell	40,635 -10,448	-20%	-$273K	0.06%	133
2026 Q1	$1.43M	Buy	51,083 +3,423	+7%	+$91.1K	0.08%	101
2025 Q4	$1.19M	Sell	47,660 -1,537	-3%	-$38.8K	0.06%	112
2025 Q3	$1.25M	Buy	49,197 +10,291	+26%	+$254K	0.06%	109
2025 Q2	$943K	Sell	38,906 -399	-1%	-$9.3K	0.04%	128
2025 Q1	$996K	Buy	39,305 +3,255	+9%	+$85.2K	0.05%	115
2024 Q4	$956K	Sell	36,050 -4,210	-10%	-$114K	0.04%	123
2024 Q3	$1.17M	Buy	40,260 +2,938	+8%	+$85.7K	0.05%	110
2024 Q2	$1.04M	Buy	37,322 +4,639	+14%	+$128K	0.05%	116
2024 Q1	$907K	Buy	32,683 +5,077	+18%	+$141K	0.04%	123
2023 Q4	$795K	Sell	27,606 -3,280	-11%	-$99.2K	0.03%	130
2023 Q3	$1.02M	Sell	30,886 -2,921	-9%	-$103K	0.04%	105
2023 Q2	$1.24M	Buy	33,807 +35	+0.1%	+$1.36K	0.05%	97
2023 Q1	$1.38M	Sell	33,772 -689	-2%	-$29.8K	0.05%	95
2022 Q4	$1.77M	Sell	34,461 -877	-2%	-$42K	0.07%	87
2022 Q3	$1.55M	Sell	35,338 -1,689	-5%	-$82.1K	0.07%	90
2022 Q2	$1.94M	Buy	37,027 +79	+0.2%	+$4.03K	0.08%	83
2022 Q1	$1.91M	Buy	36,948 +2,741	+8%	+$142K	0.07%	87
2021 Q4	$2.02M	Sell	34,207 -1,873	-5%	-$92.8K	0.07%	85
2021 Q3	$1.55M	Buy	36,080 +3,013	+9%	+$133K	0.06%	92
2021 Q2	$1.29M	Sell	33,067 -64	-0.2%	-$2.49K	0.05%	103
2021 Q1	$1.2M	Sell	33,131 -234	-0.7%	-$8.31K	0.05%	99
2020 Q4	$1.23M	Sell	33,365 -2,926	-8%	-$107K	0.06%	99
2020 Q3	$1.26M	Sell	36,291 -1,445	-4%	-$50.7K	0.06%	92
2020 Q2	$1.17M	Sell	37,736 -25	-0.1%	-$849	0.06%	91
2020 Q1	$1.17M	Buy	37,761 +6,315	+20%	+$215K	0.07%	85
2019 Q4	$1.17M	Buy	31,446 +3,307	+12%	+$118K	0.06%	94
2019 Q3	$959K	Sell	28,139 -4,092	-13%	-$149K	0.06%	94
2019 Q2	$1.32M	Sell	32,231 -26	-0.1%	-$1.03K	0.08%	83
2019 Q1	$1.3M	Sell	32,257 -2,935	-8%	-$118K	0.09%	81
2018 Q4	$1.46M	Buy	35,192 +6,417	+22%	+$266K	0.11%	80
2018 Q3	$1.2M	Buy	28,775 +5,938	+26%	+$229K	0.08%	82
2018 Q2	$786K	Buy	22,837 +109	+0.5%	+$3.73K	0.06%	90
2018 Q1	$765K	Sell	22,728 -3,395	-13%	-$117K	0.06%	90
2017 Q4	$898K	Sell	26,123 -67	-0.3%	-$2.29K	0.06%	84
2017 Q3	$887K	Sell	26,190 -1,526	-6%	-$49K	0.07%	83
2017 Q2	$883K	Sell	27,716 -4,288	-13%	-$135K	0.07%	92
2017 Q1	$1.04M	Buy	32,004 +4,574	+17%	+$144K	0.08%	88
2016 Q4	$845K	Sell	27,430 -155	-0.6%	-$4.73K	0.07%	92
2016 Q3	$886K	Sell	27,585 -152	-0.5%	-$5.08K	0.07%	100
2016 Q2	$927K	Buy	27,737 +790	+3%	+$25.2K	0.08%	97
2016 Q1	$758K	Sell	26,947 -764	-3%	-$21.8K	0.07%	101
2015 Q4	$849K	Sell	27,711 -2,355	-8%	-$74.1K	0.08%	130
2015 Q3	$896K	Sell	30,066 -649	-2%	-$20.8K	0.09%	132
2015 Q2	$977K	Sell	30,715 -16,232	-35%	-$529K	0.09%	130
2015 Q1	$1.55M	Buy	46,947 +718	+2%	+$22.8K	0.14%	133
2014 Q4	$1.37M	Sell	46,229 -4,141	-8%	-$119K	0.13%	150
2014 Q3	$1.41M	Sell	50,370 -1,211	-2%	-$34K	0.14%	149
2014 Q2	$1.45M	Buy	51,581 +53	+0.1%	+$1.51K	0.14%	142
2014 Q1	$1.57M	Sell	51,528 -5,329	-9%	-$159K	0.17%	130
2013 Q4	$1.65M	Sell	56,857 -19,200	-25%	-$559K	0.19%	120
2013 Q3	$2.07M	Buy	76,057 +349	+0.5%	+$9.5K	0.27%	100
2013 Q2	$2.01M	Buy	+75,708	New	+$2.09M	0.29%	103

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dearborn Partners's PFE Position: Q2 2026 in Review

Dearborn Partners reduced its Pfizer (PFE) stake by 20% in Q2 2026, selling an estimated $273K and leaving 40,635 shares worth $978K. The position accounts for 0.06% of the portfolio, ranked #133.

Dearborn Partners first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.07M in Q3 2013. 2,824 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Dearborn Partners held 40,635 shares of Pfizer worth $978K as of Q2 2026.
Dearborn Partners sold 10,448 Pfizer shares in Q2 2026, an estimated $273K.
Pfizer made up 0.06% of Dearborn Partners's portfolio in Q2 2026, its #133 holding.
Dearborn Partners first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Dearborn Partners's Pfizer position peaked at $2.07M in Q3 2013.
2,824 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Dearborn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.